<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43664">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02068625</url>
  </required_header>
  <id_info>
    <org_study_id>178/10</org_study_id>
    <secondary_id>2012DR2022</secondary_id>
    <nct_id>NCT02068625</nct_id>
  </id_info>
  <brief_title>Rasagiline (Azilect) - Neuroprotection for Macula-off Retinal Detachment</brief_title>
  <official_title>Rasagiline (Azilect) - Neuroprotection for Macula-off Retinal Detachment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <authority>Switzerland: Ethikkommission</authority>
    <authority>Switzerland: Swissmedic</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomised, double-blind, placebo-controlled clinical trial investigates the
      neuroprotective effect of rasagiline in patients suffering from a retinal detachment
      affecting central vision. Based on results from a study in mice suffering from retinal
      degeneration, the investigators hypothesize that rasagiline delays neurodegeneration in the
      retina and improves visual acuity outcomes after retinal detachment surgery. Rasagiline is a
      second-generation propargylamine with neuroprotective properties modulating the
      caspase-dependent pathway of programmed cell death.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background

      In previous experimental studies neuroprotection by rasagiline has been shown in rds-mice, a
      model for slow retinal degeneration. It is known from these experiments that rasagiline
      specifically delays apoptosis, but also modifies inflammation and autophagy. The
      bioavailability of the drug in the central nervous system is high, and based on the
      literature is sufficient in the retina.

      In retinal detachments the outer layers of the neurosensory retina are deprived of nutrients
      and degeneration of the photoreceptors occurs fast. This is particularly relevant in the
      macular area of the retina where the density of photoreceptors is high, such that visual
      acuity recovery can be significantly limited by photoreceptor loss.

      Objective

      To assess the neuroprotective effect of oral rasagiline (1mg daily for 7 days) administered
      perioperatively in patients undergoing surgical retinal detachment repair for central vision
      involving retinal detachments.

      Methods

      In this clinical trial, patients suffering from retinal detachments affecting the fovea get
      randomly assigned to perioperative oral treatment with either rasagiline (1mg) or placebo
      once daily for 7 days. Pharmacologic treatment is initiated at the time of hospital
      admission, usually the day before surgery. The main outcome of the study is visual acuity
      six months after surgical retinal detachment repair. Structural differences of the
      neurosensory retina between groups will be analysed by optical coherence tomography, a
      non-invasive imaging method for retinal pathology.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>ETDRS Visual Acuity</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Central retinal thickness</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured by Optical Coherence Tomography (OCT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with side effects</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Retinal Detachment</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients getting perioperative oral treatment with rasagiline (1mg daily) for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients getting perioperative oral treatment with placebo for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rasagiline</intervention_name>
    <description>Rasagiline 1mg daily orally for 7 days</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral treatment with placebo for 7 days</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Rhegmatogenous retinal detachment

          -  Central vision affected for less than 72 hours

          -  Pseudophakic

          -  Age 18 or over

          -  Not participating in other clinical trials

          -  Willing to attend follow-up visits

          -  Written informed consent

        Exclusion Criteria

          -  Phakic

          -  Narrow angle glaucoma

          -  Previous intraocular surgery other than cataract operation

          -  Retinal disease

          -  Concurrent treatment with MAO inhibitors

          -  Pregnancy

          -  Malignant arterial hypertension

          -  Liver or kidney failure

          -  Life-threatening or malignant disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sebastian Wolf</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Ophthalmology, Bern University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andreas Ebneter</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Ophthalmology, Bern University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andreas Ebneter</last_name>
    <phone>+41 (0)31 632 25 01</phone>
    <email>augenheilkunde@insel.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Corinne Stöckli</last_name>
    <phone>+41 (0)31 632 25 01</phone>
    <email>augenheilkunde@insel.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Ophthalmology, Bern University Hospital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andreas Ebneter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Eigeldinger-Berthou S, Meier C, Zulliger R, Lecaudé S, Enzmann V, Sarra GM. Rasagiline interferes with neurodegeneration in the Prph2/rds mouse. Retina. 2012 Mar;32(3):617-28. doi: 10.1097/IAE.0b013e31821e2070.</citation>
    <PMID>21878836</PMID>
  </reference>
  <reference>
    <citation>Youdim MB, Bar Am O, Yogev-Falach M, Weinreb O, Maruyama W, Naoi M, Amit T. Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J Neurosci Res. 2005 Jan 1-15;79(1-2):172-9. Review.</citation>
    <PMID>15573406</PMID>
  </reference>
  <reference>
    <citation>Travis GH. Mechanisms of cell death in the inherited retinal degenerations. Am J Hum Genet. 1998 Mar;62(3):503-8. Review.</citation>
    <PMID>9497269</PMID>
  </reference>
  <reference>
    <citation>Cook B, Lewis GP, Fisher SK, Adler R. Apoptotic photoreceptor degeneration in experimental retinal detachment. Invest Ophthalmol Vis Sci. 1995 May;36(6):990-6.</citation>
    <PMID>7730033</PMID>
  </reference>
  <reference>
    <citation>Eliash S, Shteter N, Eilam R. Neuroprotective effect of rasagiline, a monoamine oxidase-B inhibitor, on spontaneous cell degeneration in a rat model. J Neural Transm. 2005 Aug;112(8):991-1003. Epub 2005 Mar 15.</citation>
    <PMID>15765264</PMID>
  </reference>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 19, 2014</lastchanged_date>
  <firstreceived_date>February 19, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>retinal detachment</keyword>
  <keyword>rasagiline</keyword>
  <keyword>optical coherence tomography</keyword>
  <keyword>visual acuity</keyword>
  <keyword>neuroprotection</keyword>
  <keyword>azilect</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Retinal Detachment</mesh_term>
    <mesh_term>Dissociative Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rasagiline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
